Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Current Assets: 2011-2024

Historic Current Assets for Adma Biologics (ADMA) over the last 11 years, with Dec 2024 value amounting to $331.4 million.

  • Adma Biologics' Current Assets rose 26.54% to $402.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $402.7 million, marking a year-over-year increase of 26.54%. This contributed to the annual value of $331.4 million for FY2024, which is 28.95% up from last year.
  • As of FY2024, Adma Biologics' Current Assets stood at $331.4 million, which was up 28.95% from $257.0 million recorded in FY2023.
  • Adma Biologics' Current Assets' 5-year high stood at $331.4 million during FY2024, with a 5-year trough of $153.7 million in FY2020.
  • Over the past 3 years, Adma Biologics' median Current Assets value was $270.4 million (recorded in 2022), while the average stood at $286.3 million.
  • Its Current Assets has fluctuated over the past 5 years, first spiked by 35.77% in 2021, then declined by 4.95% in 2023.
  • Adma Biologics' Current Assets (Yearly) stood at $153.7 million in 2020, then spiked by 35.77% to $208.7 million in 2021, then climbed by 29.55% to $270.4 million in 2022, then declined by 4.95% to $257.0 million in 2023, then climbed by 28.95% to $331.4 million in 2024.